FDA looking to abandon expert reviews of new drugs
CBS America · Just In
CBS America
Just In
The Food and Drug Administration is looking to shift away from policies dating back decades of having outside experts and panels review new drug applications. These external committees have been used since the 1970s in order to better advise health officials facing difficult decisions.
Breakdown
- FDA plans to stop using external expert panels for new drug application reviews.
- These panels have advised the FDA since the 1970s, providing specialized input on drug safety and efficacy. 10s
- FDA leadership believes internal reviews and public communications are sufficient for transparency. 1m 14s
- Some observers question the move, emphasizing the panels' influential role in drug safety decisions. 1m 28s